Protein mono-ADP-ribosyltransferase PARP3 (PARP3)
Homo sapiens — UniProt Q9Y6F1
Data last refreshed: (UniProt release unknown)
Key facts
Protein mono-ADP-ribosyltransferase PARP3 (PARP3) is a protein from Homo sapiens identified by UniProt accession Q9Y6F1, 533 residues long. MolForge cross-references it against 5 known binders and 143 disease associations.
- UniProt accession: Q9Y6F1; gene symbol PARP3.
- Organism: Homo sapiens.
- Length: 533 amino acids.
- Approved drugs acting on it (DrugCentral): Olaparib and Rucaparib.
- Top disease associations (Open Targets): ovarian cancer, ovarian carcinoma and ovarian neoplasm.
- 3D structure: AlphaFold model available.
Target properties
| Protein name | Protein mono-ADP-ribosyltransferase PARP3 |
|---|---|
| UniProt accession | Q9Y6F1 |
| Gene | PARP3 |
| Organism | Homo sapiens |
| Length | 533 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | — |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). Approved drug exists
| Druggability tier | MEDIUM |
|---|---|
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs acting on this target (2)
Approved drugs whose DrugCentral mechanism of action is this protein, most potent first.
Disease associations (143)
Diseases linked to this target (Open Targets).
- ovarian cancer · score 0.57
- ovarian carcinoma · score 0.55
- ovarian neoplasm · score 0.53
- neoplasm · score 0.52
- prostate cancer · score 0.49
- cancer · score 0.46
- breast cancer · score 0.40
- non-small cell lung carcinoma · score 0.38
- prostate adenocarcinoma · score 0.37
- prostate carcinoma · score 0.35
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|---|---|---|---|
| AF-Q9Y6F1-F1 | alphafold | PREDICTED | 85.39 | — |
Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q9Y6F1.
Amino-acid sequence (533 residues)
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
Which approved drugs target PARP3?
DrugCentral lists 2 approved drugs whose mechanism of action is PARP3: Olaparib and Rucaparib.
Which diseases are associated with PARP3?
The strongest Open Targets associations for PARP3 are ovarian cancer, ovarian carcinoma, ovarian neoplasm, neoplasm and prostate cancer.
How long is the PARP3 protein?
The Homo sapiens PARP3 protein (UniProt Q9Y6F1) is 533 amino acids long.
Browse: Targets: P · all protein targets A–Z · drugs A–Z.
Sources
- UniProtKB Q9Y6F1 — name, gene, function, sequence, keywords (CC BY 4.0)
- AlphaFold DB Q9Y6F1 — predicted 3D structure (CC BY 4.0)
- DrugCentral — approved drugs and mechanism-of-action links (CC BY-SA 4.0)
- Open Targets Platform — disease associations and tractability (CC0)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.